Abstract 1635P
Background
Assessment of germline BRCA1-2 pathogenic variants (gPV) is routinely recommended in Pancreatic Ductal Adenocarcinoma (PDAC) patients (pts), due to clinical-epidemiological relevance. Limited data are available on the prevalence of gPV in other cancer predisposition genes, including the DNA Damage Response (DDR) system.
Methods
Clinical data of consecutive PDAC pts, of any age and stage, tested with a multigene germline panel between January 2018 and March 2023 in five Italian Institutes were collected. A descriptive analysis of gPV (class 4 and 5) frequency, clinical variables and risk factors, was performed. Since gene panels did not overlap across all Institutes, it was difficult to properly estimate the real prevalence of gPV and to compare the clinical characteristics of all wild type with any-PV population, as screened pts/gene also varied (291-1200). Herein we report the best scenario that may result in rates underestimation.
Results
Among the 1200 pts included in the analysis, 169 (14%) had a gPV (any-PV). 23/73 genes had a gPV in ≥ 1 patient. Genes with a gPV in >1% of tested pts were ATM (36/1200 - 3.0%), BRCA2 (35/1200 - 2.9%), CDKN2A (23/942 - 2.4%), BRCA1 (18/1200 - 1.5%), CHEK2 (11/838 - 1.3%), and COL7A1 (5/447 - 1.1%). Characteristics of the main cohorts are shown in the table. The risk of having a genomic gPV was ≥9% in all the subgroups of pts considered for the different variables, including >73 years old pts (11%). Moreover, 25% of pts with age 41-50, 18% of obese pts and 21% of pts with PDAC/breast/ovarian/prostate cancer/melanoma family history harbored a gPV.
Table: 1635P
Patients’ characteristics [N (%)]
Wild Type1031 | Any Pathogenic Variant169 | BRCA1-2 53 | ATM36 | CDKN2A23 | |
Age | |||||
Median | 66 | 63 | 60 | 63 | 64 |
Range | 28-89 | 26-83 | 44-79 | 38-83 | 51-83 |
≤50 | 84 (8) | 24 (14) | 10 (19) | 5 (14) | 0 |
51-73 | 753 (73) | 122 (72) | 41 (77) | 25 (69) | 18 (78) |
≥74 | 194 (19) | 23 (14) | 2 (4) | 6 (17) | 5 (22) |
Gender | |||||
Female | 525 (51) | 79 (47) | 26 (49) | 14 (39) | 10 (43) |
Stage | |||||
I-II | 256 (27) | 32 (21) | 6 (12) | 12 (38) | 5 (26) |
III | 192 (20) | 31 (20) | 10 (19) | 8 (26) | 2 (11) |
IV | 511 (53) | 92 (59) | 36 (69) | 11 (36) | 12 (63) |
NA | 72 | 14 | 1 | 5 | 4 |
CA19.9 | |||||
Median≤35 | 648191 (22) | 73824 (17) | 9838 (18) | 3882 (6) | 1037 (44) |
>35 | 666 (78) | 113 (83) | 36 (82) | 29 (94) | 9 (56) |
NA | 174 | 32 | 9 | 5 | 7 |
Family history | |||||
Yes | 383 (41) | 103 (65) | 38 (75) | 21 (64) | 15 (79) |
No | 554 (59) | 55 (35) | 13 (25) | 12 (36) | 4 (21) |
NA | 94 | 11 | 2 | 3 | 4 |
NA: not available
Conclusions
Our study highlighted a remarkable prevalence of gPV in cancer predisposition and DDR genes in a large cohort of PDAC pts. These findings endorse the implementation of an extended multigene germline panel to be offered to all PDAC pts, irrespective of age, stage, and personal/family history.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Reni.
Funding
Has not received any funding.
Disclosure
G. Giordano: Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca, Bayer; Financial Interests, Personal and Institutional, Financially compensated role: Servier, Amgen, Seagen, Novartis, Ipsen. M. Reni: Financial Interests, Personal and Institutional, Advisory Board: Eli Lilly, Panavance, Celgene, AstraZeneca, Viatris, Merck Sharp & Dohme, Servier, Sotio, Baxter; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22